2021 CMSC Annual Meeting

CHOICES & CONTROVERSIES IN MS MANAGEMENT: A PRO/CON CASE-BASED DISCUSSION

CREDITS: CME, CNE, CPE, PA
Expiration: 30-Apr-22
Level of Information: Intermediate

This interactive case-based symposium will highlight contemporary controversies in MS disease management. Three debates will be moderated by the symposium chairs around the following questions: 1) Does early MS treatment prevent future disability, 2) Is rituximab an acceptable MS therapy alternative for the newer B-cell therapies, and 3) Can therapies approved for active secondary progressive MS be used for inactive secondary progressive MS. The speakers in this symposium are seasoned MS clinicians and will be presented with a clinical case to debate and make their points. Questions from the audience will be encouraged and integrated into this symposium.

Presentations and Speakers

Introduction Mitchell T. Wallin, MD, MPH, FAAN; Michelle Cameron, MD, PT, MCR
Treatment of Active MS will Prevent Disability Progression – Yes Olaf Stuve, MD, PhD
Treatment of Active MS will Prevent Disability Progression – No John R. Rinker, II, MD
Rituximab is an Acceptable Alternative for Newer B-Cell Therapies – Yes Michelle Cameron, MD, PT, MCR
Rituximab is an Acceptable Alternative for Newer B-Cell Therapies – No Mitchell T. Wallin, MD, MPH, FAAN
Therapies Approved for Active SPMS should also be Used in Inactive SPMS – Yes Rebecca Spain, MD, MSPH, FAAN
Therapies Approved for Active SPMS should also be Used in Inactive SPMS – No Natasha M. Antonovich, PharmD, BCPS
Discussion / Q&A Panel

You can only claim credits for this On-demand Video if you have not done so for the Live Event.